Search Within

Alexander Noor Shoushtari

Formats
  1. Journal Article (112)
  2. Meeting Abstract (105)
  3. Research Letter (11)
  4. Editorial (7)
  5. Review (4)
  6. Book Section (3)
  7. Guidelines (1)
  8. Miscellaneous (1)
Groups
  1. Department of Medicine (244)
  2. Hematologic Malignancies, Division of (244)
  3. Melanoma Disease Management Team (244)
  4. Melanoma and Immunotherapeutics Service (244)
  5. Solid Tumor Oncology Division (244)
  6. GSK Faculty (86)

More Groups

People
  1. Michael Postow (63)
  2. Jedd Wolchok (49)
  3. Margaret Callahan (45)
  4. Paul Chapman (45)
  5. Katherine Panageas (34)
  6. Parisa Momtaz (32)

More People

Years
  1. 2025 (4)
  2. 2024 (22)
  3. 2023 (25)
  4. 2022 (38)
  5. 2021 (38)
  6. 2020 (28)

More Years

Publications
  1. Journal of Clinical Oncology (66)
  2. Annals of Oncology (22)
  3. Journal for ImmunoTherapy of Cancer (17)
  4. Clinical Cancer Research (11)
  5. Cancer Research (7)
  6. Melanoma Research (5)

More Publications

Publishers
  1. American Society of Clinical Oncology (69)
  2. Oxford University Press (29)
  3. American Association for Cancer Research (21)
  4. Biomed Central Ltd (21)
  5. Nature Publishing Group (14)
  6. Elsevier Inc. (13)

More Publishers

Results (244)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Results from phase IB study of tebentafusp (tebe) in combination with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM)
    Meeting Abstract

    Hamid, O.; Hassel, J.; Shoushtari, A.; Meier, F.; Bauer, T.; Salama, A.; Kirkwood, J.; Ascierto, P.; Lorigan, P.; Mauch, C.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Consistent pattern of immune activation induced by oncolytic adenovirus ONCOS-102 across diverse types of solid tumors
    Meeting Abstract

    Kuryk, L.; Moller, A. S.; Kumar, S.; Shoushtari, A.; Ares, L. P.; Jaderberg, M.; Wiklund, E. D.; Levitsky, V.
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Characterization of cytokine release syndrome (CRS) following treatment with tebentafusp in patients (pts) with previously treated (2L+) metastatic uveal melanoma (mUM)
    Meeting Abstract

    Carvajal, R. D.; Sato, T.; Butler, M. O.; Sacco, J. J.; Shoushtari, A. N.; Hassel, J. C.; Ikeguchi, A.; Hernandez-Aya, L. F.; Rioth, M.; Hamid, O.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Overall survival benefit from tebentafusp in patients with best response of progressive disease
    Meeting Abstract

    Joshua, A. M.; Baurain, J. F.; Piperno-Neumann, S.; Nathan, P.; Hassel, J. C.; Butler, M. O.; Schlaak, M.; Sullivan, R.; Ochsenreither, S.; Dummer, R.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Characterization of liver function tests (LFTs) following tebentafusp (tebe) in previously treated (2L+) metastatic uveal melanoma (mUM) patients (pts)
    Meeting Abstract

    Sato, T.; Carvajal, R. D.; Sacco, J. J.; Shoushtari, A. N.; Hassel, J. C.; Ikeguchi, A.; Hernandez-Aya, L. F.; Nathan, P.; Rioth, M.; Hamid, O.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Co-primary endpoint of overall survival for tebentafusp (tebe)-induced rash in a phase 3 randomized trial comparing tebe versus investigator's choice (IC) in first-line metastatic uveal melanoma
    Meeting Abstract

    Hassel, J. C.; Rutkowski, P.; Baurain, J. F.; Butler, M. O.; Schlaak, M.; Sullivan, R.; Ochsenreither, S.; Dummer, R.; Kirkwood, J. M.; Joshua, A. M.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Discrepancies in response and immune-related adverse events (irAE) of anti-PD-1 monotherapy between races and primary sites in patients (pts) with advanced nonacral cutaneous melanoma (NACM)
    Meeting Abstract

    Bai, X.; Shoushtari, A. N.; Warner, A. B.; Quach, H.; Cann, C. G.; Zhang, M.; Pallan, L.; Harvey, C.; Si, L.; Tang, B.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Overall survival in patients who received checkpoint inhibitors after completing tebentafusp in a phase 3 randomized trial of first-line metastatic uveal melanoma
    Meeting Abstract

    Orloff, M.; Carvajal, R. D.; Shoushtari, A. N.; Sacco, J. J.; Schlaak, M.; Watkins, C.; Abdullah, S. E.; Goodall, H.; Butler, M. O.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Clinical characteristics of SF3B1 mutant (mut) uveal melanoma (UM) and response to immune checkpoint inhibition (ICI)
    Meeting Abstract

    Grimes, J.; Shoushtari, A. N.; Orloff, M.; Khan, S.; Chiuzan, C.; Hsiao, S. J.; McDonnell, D.; Marr, B. P.; Carvajal, R. D.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Propensity weighted indirect treatment comparison of nivolumab (NIVO) versus placebo (PBO) as adjuvant therapy for resected melanoma: A number needed to treat and overall survival analysis
    Meeting Abstract

    Weber, J. S.; Poretta, T.; Stwalley, B.; Sakkal, L.; Du, E. X.; Wang, T.; Chen, Y.; Wang, Y.; Betts, K. A.; Shoushtari, A. N.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save